Fundraising Fox

Immunic

NASDAQ: IMUX

New York, US · Delaware corporation · 5 known investors

Biotechnology company developing orally available therapies for chronic inflammatory and autoimmune diseases.

Biotech

Founders & leadership

AM
Andreas MuehlerCo-founder
DVDaniel Vitt
Daniel VittinCo-founder
JT
JASON TARDIOExecutive
GW
GLENN WHALEYExecutive
IS
INDERPAL SINGHExecutive
PW
Patrick WalshExecutive
HK
Hella KohlhofNamed on SEC filing
MM
Monika Maria TornsenNamed on SEC filing
JN
Jorg NeermanNamed on SEC filing
PC
Phillip CroxfordNamed on SEC filing
AS
Aron SternNamed on SEC filing
JM
J. Michael MillisNamed on SEC filing

Investors · 5

Bayern KapitalLandshut · $275K – $55M
bmp VenturesBerlin · $550K – $16.5M
Fund+Leuven · $5.5M – $16.5M
Pontifax Venture CapitalHerzeliya · $6.3M – $128M
Omega FundsreportedBostonvia Vincent Ossipow · board

Reported raises · per SEC filings

Form D private placements

$386.8M disclosed across 6 rounds · 2012–2026

▶$200MraisedMar 2026 · 43 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • THORVALD NAGELDirector
  • JASON TARDIOExecutive Officer
  • TAMAR HOWSONDirector
  • GLENN WHALEYExecutive Officer
  • INDERPAL SINGHExecutive Officer
  • HELLA KOHLHOFExecutive Officer
  • PATRICK WALSHExecutive Officer
  • ANDREAS MUEHLERExecutive Officer
  • BARCLAY PHILLIPSDirector
  • DUANE NASHDirector
  • SIMONA SKERJANECDirector
  • DANIEL VITTExecutive Officer, Director
  • RICHARD RUDICKDirector
  • JOERG NEERMANDirector
Offering amount
$200M
Amount sold
$200M
Sales commissions
$12M
Placement agents
BROOKLINE CAPITAL MARKETS, A DIVISION OF ARCADIA SECURITIES, LLC, Leerink Partners LLC, STIFEL, NICOLAUS & COMPANY, INCORPORATED, GUGGENHEIM SECURITIES, LLC, WILLIAM BLAIR & COMPANY, LLC, LIFESCI CAPITAL LLC, B. RILEY SECURITIES, INC.
First sale
Feb 2026
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$80MraisedJan 2024 · 19 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Andreas MuehlerExecutive Officer
  • Barclay PhillipsDirector
  • Inderpal SinghExecutive Officer
  • Daniel VittExecutive Officer, Director
  • Patrick WalshExecutive Officer
  • Duane NashDirector
  • Tamar HowsonDirector
  • Jorg NeermannDirector
  • Richard RudickDirector
  • Glenn WhaleyExecutive Officer
  • Maria TornsenDirector
  • Hella KohlhofExecutive Officer
Offering amount
$240M
Amount sold
$80M
Sales commissions
$4.8M
First sale
Jan 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$60MraisedOct 2022 · 14 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Andreas MuehlerExecutive Officer
  • Vincent OssipowDirector
  • Daniel VittExecutive Officer, Director
  • Monika Maria TornsenDirector
  • Jorg NeermanDirector
  • Inderpal SinghExecutive Officer
  • Glenn WhaleyExecutive Officer
  • Hella KohlhofExecutive Officer
  • Patrick WalshExecutive Officer
  • Barclay PhillipsDirector
  • Tamar HowsonDirector
  • Duane NashDirector
Offering amount
$60M
Amount sold
$60M
Sales commissions
$3.6M
First sale
Oct 2022
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$13.9MraisedMar 2014 · 37 investors · Biotechnology
Rule 506(c)
Officers, directors & promoters on the filing
  • Kameron MaxwellExecutive Officer
  • Randolph C. SteerDirector
  • Errol R. HalperinDirector
  • Andrew HenryExecutive Officer
  • Michael V. SwansonExecutive Officer
  • Muneer A, SatterDirector
  • Andrea LoewenExecutive Officer
  • Douglas GodshallDirector
  • J. Michael MillisDirector
  • Duane NashExecutive Officer
  • Aron P. SternExecutive Officer
  • Richard MurawskiExecutive Officer
  • Terence E. WintersExecutive Officer, Director
  • Jean-Jacques BienaimeDirector
  • Robert A. AshleyExecutive Officer
  • Lowell E. SearsDirector
  • Phillip M. CroxfordDirector
Offering amount
$13.9M
Amount sold
$13.9M
First sale
Jan 2014
Incorporated
Corporation, Delaware
Federal exemptions
06c
Full filing on SEC EDGAR ↗
▶$32MraisedJan 2014 · 62 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Michael V. SwansonExecutive Officer
  • Andrea LoewenExecutive Officer
  • Errol R. HalperinDirector
  • Robert A. AshleyExecutive Officer
  • Richard MurawskiExecutive Officer
  • Kemeron MaxwellExecutive Officer
  • J. Michael MillisDirector
  • Douglas GodshallDirector
  • Duane NashExecutive Officer
  • Andrew HenryExecutive Officer
  • Aron P. SternExecutive Officer
  • Phillip M. CroxfordDirector
  • Jean-Jacques BienaimeDirector
  • Terence E. WintersExecutive Officer, Director
  • Muneer A, SatterDirector
  • Randolph C. SteerDirector
  • Lowell E. SearsDirector
Offering amount
$32M
Amount sold
$32M
First sale
Feb 2013
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$929.8KraisedFeb 2012 · 7 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Phillip CroxfordDirector
  • Aron SternExecutive Officer
  • J. Michael MillisDirector
  • Robert AshleyExecutive Officer
  • Terry WintersExecutive Officer, Director
  • Randolph SteerDirector
Offering amount
$1.5M
Amount sold
$929.8K
Proceeds to insiders
$108.8K
First sale
Feb 2012
Incorporated
Corporation, Delaware
Federal exemptions
06, 46
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

Immunic Q3 EPS Lifted by Brookline Capital Markets - Markets Dailythemarketsdaily.com · Aug 2026Immunic (IMUX) posts larger Q2 2026 loss but extends cash runway into 2027stocktitan.net · Aug 2026Immunic (Nasdaq: IMUX) raises $200M, lifts cash to $155M amid higher lossesstocktitan.net · Aug 2026Immunic raises $200M and posts Q1 2026 loss | IMUX Quarterly Report (10-Q)stocktitan.net · May 2026Funding to support Immunic Phase 3 MS trials, commercializationmultiplesclerosisnewstoday.com · Feb 2026Biotech Immunic raises up to $400M to push an oral MS drug to marketstocktitan.net · Feb 2026

Frequently asked questions

What does Immunic do?
Biotechnology company developing orally available therapies for chronic inflammatory and autoimmune diseases.
Who founded Immunic?
Immunic was founded by Andreas Muehler, Daniel Vitt.
Who are Immunic's investors?
Immunic's investors include Bayern Kapital, bmp Ventures, Fund+, Pontifax Venture Capital, Omega Funds.
How much funding has Immunic raised?
Immunic has disclosed $386.8M raised across 6 rounds.
Where is Immunic headquartered?
Immunic is headquartered in New York, US.